Hematopoietic stem cell transplantation: a global perspective.
Hematopoietic stem cell transplantation: a global perspective.
复制标题
DOI：
10.1001/jama.2010.491
复制
发表时间：
2010-04-28
影响因子：
120.7
通讯作者：
Kodera, Yoshihisa
中科院分区：
文献类型：
--
作者：
Gratwohl, Alois;Baldomero, Helen;Aljurf, Mahmoud;Pasquini, Marcelo C.;Bouzas, Luis Fernando;Yoshimi, Ayami;Szer, Jeff;Lipton, Jeff;Schwendener, Alvin;Gratwohl, Michael;Frauendorfer, Karl;Niederwieser, Dietger;Horowitz, Mary;Kodera, Yoshihisa
造血干细胞移植（HSCT）需要大量的基础设施。在全球一级，对它的使用及其相关因素知之甚少。确定目前HSCT的使用情况，评估其应用的差异，并探讨全球范围内宏观经济因素与移植率的关系。按主要适应症、供体类型和干细胞来源分类的2006年全球同种异体和自体HSCT数量的结构化收集。全球血液和骨髓移植网络（WBMT）是一个全球性的临床HSCT非营利性伞式组织。2006年在任何参与国家接受同种异体或自体HSCT治疗任何适应症的所有患者。按适应症、供体类型和国家分列的移植率（每1000万居民中的HSCT数量）; HSCT使用的主要差异描述;报告国与移植率相关的宏观经济因素。71个国家的1 '327个中心报告了50'417例首次HSCT，21'516例同种异体（43%），28'901例自体（57（17'049例（34%; 89%同种异体）），淋巴瘤（27，492（54%; 87%自体））、实体瘤（2，925（6%，95%自体））、非恶性病症（2，593（5%; 92%同种异体））或“其他”358（1%）。使用同种异体或自体HSCT、使用无关或家族供体进行同种异体HSCT以及疾病适应症的比例在国家和大陆地区之间存在显著差异。在线性回归分析中，政府卫生保健支出（r2 = 77.33），团队密度（r2 =76.28），人类发展指数（r2 = 74.36）和国民总收入/人均（r2 = 74.04）与移植率的相关性最高。HSCT是当今公认的治疗方法，在全球范围内有不同的用途和需求。资源的可用性、政府的支持以及患者获得团队的机会被认为是提高移植率的关键因素。
Hematopoietic stem cell transplantation (HSCT) requires significant infrastructure. Little is known on its use and the factors associated with it on a global level. To determine current use of HSCT, to assess differences in its application and to explore associations of macroeconomic factors with transplant rates on a global level. Structured worldwide collection of numbers of allogeneic and autologous HSCT by main indication, donor type and stem cell source for the year 2006. Worldwide Network for Blood and Marrow Transplantation (WBMT), a global non-profit umbrella organization for clinical HSCT. All patients with an allogeneic or autologous HSCT for any indication transplanted in 2006 within any of the participating countries. none Transplant rates (number of HSCT per 10 million inhabitants) by indication, donor type and country; description of main differences in HSCT use; macroeconomic factors of reporting countries associated with transplant rates. There were 50’417 first HSCT, 21’516 allogeneic (43%), 28’901 autologous (57%) reported from 1’327 centers in 71 countries for leukemia (17’049 (34%; 89% allogeneic)), lymphoma (27’492 (54%; 87% autologous)), solid tumors (2’925 (6%, 95% autologous)), non-malignant disorder (2’593 (5%; 92% allogeneic)) or, “others” 358 (1%). Use of allogeneic or autologous HSCT, use of unrelated or family donors for allogeneic HSCT and proportions of disease indications varied significantly between countries and continental regions. In linear regression analyses, Government Health Care Expenditures (r2 = 77.33), team density (r2 =76.28), Human Development Index (r2 = 74.36) and Gross National Income /Capita (r2 = 74.04) showed the highest association with transplant rates. HSCT is an accepted therapy today with different use and needs worldwide. Availability of resources, Governmental support and, access for patients to a team were identified as key factors for higher transplant rates.
登录
查看更多内容
影响因子：
4.8
作者：
Daikeler, T.;Huegle, T.;Gratwohl, A.
通讯作者：
Gratwohl, A.
DOI：
10.1016/j.bbmt.2008.12.497
发表时间：
2009-03
期刊：
Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation
影响因子：
--
作者：
Giralt S;Ballen K;Rizzo D;Bacigalupo A;Horowitz M;Pasquini M;Sandmaier B
通讯作者：
Sandmaier B
影响因子：
0.9
作者：
Aubrey, P.;Arber, S.;Tyler, M.
通讯作者：
Tyler, M.
影响因子：
10.1
作者：
Gratwohl, Alois;Baldomero, Helen;Frauendorfer, Karl
通讯作者：
Frauendorfer, Karl
影响因子：
6.2
作者：
Gratwohl, Alois;Stern, Martin;Niederwieser, Dietger
通讯作者：
Niederwieser, Dietger